FrancophonIA/ELRC3.0 huggingface dataset:
English: Based on in vitro data, repaglinide appears to be a substrate for active hepatic uptake (organic anion transporting protein OATP1B1).
Maltese: Minn informazzjoni in vitro, jidher li repaglinide huwa sustrat għall-assorbiment epatiku attiv (proteina organika għat-trasport anijoniku OATP1B1).
English: This may happen:
Maltese: Dan jista' jiġri:
English: Do not take this medicine if you are under 18 years of age.
Maltese: Tiħux din il-mediċina jekk għandek inqas minn 18-il sena.
English: Combination with Neutral Protamine Hagedorn (NPH) insulin or thiazolidinediones
Maltese: It-teħid flimkien mal-insulina Neutral Protamine Hagedorn (NPH) jew ma' thiazolidinediones
English: Other medicines and Enyglid
Maltese: Mediċini oħra u Enyglid
English: The following substances may reduce the hypoglycaemic effect of repaglinide: Oral contraceptives, rifampicin, barbiturates, carbamazepine, thiazides, corticosteroids, danazol, thyroid hormones and sympathomimetics.
Maltese: Kontraċettivi orali, rifampicin, barbituriċi, carbamazepine, tijażidi, corticosterojdi, danazol, ormoni tat-tirojde u simpatomimetiċi.
English: Each tablet contains 0.5 mg, 1 mg, 2 mg repaglinide.
Maltese: Kull pillola fiha 0,5 mg, 1 mg, 2 mg repaglinide.
English: No clinically relevant differences were seen in the pharmacokinetics of repaglinide, when repaglinide was administered 0, 15 or 30 minutes before a meal or in fasting state.
Maltese: Ma deherx li kien hemm xi differenzi klinikament rilevanti fil-farmakokinetika ta' repaglinide, meta repaglinide ngħata 0, 15 jew 30 minuta qabel ikla jew fi stat ta' sawm.
English: Boxes of 30, 60, 90, 120, 180, 270 or 360 tablets in blisters are available.
Maltese: Kaxxi ta' 30, 60, 90, 120, 180, 270 u 360 pillola fil-folji huma disponibbli.
English: The maximum recommended daily dose is 16 mg.
Maltese: Id-doża massima rakkomandata ta' kuljum hi ta' 16 mg.
English: Elderly No clinical studies have been conducted in patients >75 years of age.
Maltese: Anzjani Ma sarux studji kliniċi fuq pazjenti > 75 sena.
English: Enyglid 1 mg tablets
Maltese: Enyglid 1 mg pilloli
English: Marketing Authorisation Holder KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
Maltese: Id-Detentur tal-Awtorizzazzjoni għat- Tqegħid fis-Suq KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Is-Slovenja
English: In vitro data indicate that repaglinide is metabolised predominantly by CYP2C8, but also by CYP3A4.
Maltese: Informazzjoni in vitro tindika li repaglinide hu metabolizzat il-biċċa l-kbira minn CYP2C8, iżda wkoll minn CYP3A4.
English: It cannot be excluded that other inducers, e.g. phenytoin, carbamazepine, phenobarbital, St John's wort, may have a similar effect.
Maltese: Ma jistax jiġi eskluż li indutturi oħrajn, eż. phenytoin, carbamazepine, phenobarbital, St.
English: Enyglid 2 mg tablets
Maltese: Enyglid 2 mg pilloli
English: Enyglid 0.5 mg tablets
Maltese: Enyglid 0,5 mg pilloli
English: In an interaction study with healthy volunteers, co-administration of deferasirox (30 mg/kg/day, 4 days), a moderate inhibitor of CYP2C8 and CYP3A4, and repaglinide (single dose, 0.5 mg) resulted in an increase in repaglinide systemic exposure (AUC) to 2.3-fold (90% CI [2.03-2.63]) of control, a 1.6-fold (90% CI [1.42-1.84]) increase in Cmax, and a small, significant decrease in blood glucose values.
Maltese: F'studju ta' interazzjoni f'volontiera b'saħħithom, it-teħid flimkien ta' deferasirox (30 mg/kg/ġurnata, 4 ġranet), inibitur moderat ta' CYP2C8 u CYP3A4 u repaglinide (doża waħda, 0.5 mg) irriżulta f'żieda fl-espożizzjoni sistemika ta' repaglinide (AUC) ta' 2.3 darbiet tal-kontrol (90% CI [2.03-2.63]) l, żieda fis-Cmax ta' 1.6 darbiet (90% CI [1.42-1.84]) u tnaqqis żgħir iżda sinifikanti fil-valuri tazzokkor fid-demm.
English: The total maximum daily dose should not exceed 16 mg.
Maltese: Id-doża massima totali ta' kuljum m'għandiex taqbeż 16 mg.
English: Enyglid 0.5 mg tablets Enyglid 1 mg tablets Enyglid 2 mg tablets
Maltese: Enyglid 0,5 mg pilloli Enyglid 1 mg pilloli Enyglid 2 mg pilloli
English: Enyglid 0.5 mg tablets Enyglid 1 mg tablets Enyglid 2 mg tablets Repaglinide
Maltese: Enyglid 0,5 mg pilloli Enyglid 1 mg pilloli Enyglid 2 mg pilloli Repaglinide
English: The AUC (SD) after 2 mg single dose exposure (4 mg in patients with hepatic insufficiency) was 31.4 ng/ml x hr (28.3) in healthy volunteers, 304.9 ng/ml x hr (228.0) in patients with hepatic insufficiency, and 117.9 ng/ml x hr (83.8) in the elderly type 2 diabetic patients.
Maltese: L-AUC (SD) wara espożizzjoni ta' doża waħda ta' 2 mg (4 mg f'pazjenti b'insuffiċjenza tal-fwied) kienet ta' 31.4 ng/ml x siegħa (28.3) f'voluntiera b'saħħithom, 304.9 ng/ml x siegħa (228.0) f'pazjenti b'insuffiċjenza tal-fwied, u 117.9 ng/ml x siegħa (83.8) filpazjenti anzjani bid-dijabete tat-tip 2.
English: Repaglinide pharmacokinetics are characterised by low volume of distribution, 30 L (consistent with distribution into intracellular fluid) and is highly bound to plasma proteins in humans (greater than
Maltese: Il-farmakokinetika ta' repaglinide hija kkaratterizzata minn volum baxx ta' distribuzzjoni, 30 L (konsistenti ma' distribuzzjoni fil-fluwidu intraċellulari) u jintrabat sew ma' proteini tal-plażma filbniedem (aktar minn 98%).
English: One epidemiological study suggested an increased risk of acute coronary syndrome in repaglinide treated patients as compared to sulfonylurea treated patients (see sections 4.4 and 4.8).
Maltese: Studju epidemjoloġiku wieħed wera żieda fir-riskju tas-sindromu koronarju akut f'pazjenti kkurati b'repaglinide meta mqabbla ma' pazjenti kkurati b'sulfonylureas (ara sezzjonijiet 4.4 u 4.8).
English: Co-administration of 100 mg itraconazole, an inhibitor of CYP3A4, has also been studied in healthy volunteers, and increased the AUC by 1.4-fold.
Maltese: It-teħid flimkien ma' 100 mg ta' itraconazole, inibitur ta' CYP3A4, kien studjat ukoll f'voluntiera b'saħħithom, u żied l-AUC b'1.4 darbiet.
English: β-blocking medicinal products may mask the symptoms of hypoglycaemia.
Maltese: Prodotti mediċinali β-blokkanti jistgħu jaħbu s-sintomi ta' l-ipogliċemija.
English: * see section Description of selected adverse reactions below
Maltese: * ara s-sezzjoni Deskrizzjoni ta' reazzjonijiet avversi partikulari aktar 'l isfel
English: Half-life was prolonged from 1.3 hr to 3.7 hr, resulting in possibly enhanced and prolonged blood glucose-lowering effect of repaglinide, and plasma repaglinide concentration at 7 hr was increased 28.6-fold by gemfibrozil.
Maltese: Kien hemm żieda fil-half-life minn 1.3 sa 3.7 sigħat, li jirriżulta possibbilment f'effett ipogliċemizzanti ta' repaglinide aktar qawwi u aktar fit-tul u l-konċentrazzjoni fil-plażma ta' repaglinide fis-seba' siegħa żdied b'28.6 darbiet bit-teħid ta' gemfibrozil.
English: Tel.: + 48 (0)22 573 7500
Maltese: KRKA-POLSKA Sp.z o.o. Tel.: + 48 (0)22 573 7500
English: Based on the experience with repaglinide and with other hypoglycaemic medicinal products the following adverse reactions have been seen: Frequencies are defined as: - Common (1/100 to <1/10) - Uncommon (1/1,000 to <1/100) - Rare (1/10,000 to <1/1,000) - Very rare (<1/10,000) - Not known (cannot be estimated from the available data)
Maltese: Il-frekwenzi huma mfissra bħala: komuni (≥ 1/100 sa < 1/10); mhux komuni (≥ 1/1000 sa 1/100); rari (≥ 1/10,000 sa < 1/1,000); rari ħafna (< 1/10,000) u mhux magħruf (ma tistax tittieħed stima mid-dejta disponibbli)
English: Repaglinide is almost completely metabolised, and no metabolites with clinically relevant hypoglycaemic effect have been identified.
Maltese: Repaglinide jiġi mmetabolizzat kważi kollu, u ma ġewx identifikati metaboli b'effett ipogliċemiku ta' rilevanza klinika.
English: Co-administration of cimetidine, nifedipine, oestrogen, or simvastatin with repaglinide, all CYP3A4 substrates, did not significantly alter the pharmacokinetic parameters of repaglinide.
Maltese: It-teħid fl-istess ħin ta' cimetidine, nifedipine, oestrogen, jew simvastatin ma' repaglinide, kollha sustanzi li fuqhom jaġixxi CYP3A4, ma bidlux b'mod sinifikanti l-parametri farmakokinetiċi ta' repaglinide.
English: When repaglinide was given 24 hours after the last rifampicin dose, an 80% reduction of the repaglinide AUC was observed (effect of induction alone).
Maltese: Meta repaglinide ngħata 24 siegħa wara l-aħħar doża ta' rifampicin, kien osservat tnaqqis ta' 80% flAUC ta' repaglinide (effett ta' l-induzzjoni waħidha).
English: Rifampicin, a potent inducer of CYP3A4, but also CYP2C8, acts both as an inducer and inhibitor of the metabolism of repaglinide.
Maltese: Rifampicin, li b'mod qawwi jikkawża l-induzzjoni ta' CYP3A4, iżda wkoll ta' CYP2C8, jaġixxi kemm ta' induttur u kemm ta' inibitur fil-metaboliżmu ta' repaglinide.
English: Repaglinide has been given with weekly escalating doses from 4 - 20 mg four times daily in a 6 week period.
Maltese: Repaglinide ngħata b'żieda fid-doża kull ġimgħa minn 4-20 mg erba' darbiet kuljum f'perijodu ta' 6 ġimgħat.
English: In an interaction study with healthy volunteers, co-administration of clopidogrel (300 mg loading dose), a CYP2C8 inhibitor, increased repaglinide exposure (AUC0-∞) 5.1-fold and continued administration (75 mg daily dose) increased repaglinide exposure (AUC0-∞) 3.9-fold.
Maltese: F'studju ta' interazzjoni f'volontiera b'saħħithom, it-teħid flimkien ma' clopidogrel (doża ta' kkargar ta' 300 mg), inibitur ta' CYP2C8, żied l-espożizzjoni sistemika ta' repaglinide (AUC0-∞) b'5.1 darbiet u b'teħid kontinwu (doża ta' 75 mg kuljum) żied l-espożizzjoni sistemika ta' repaglinide (AUC0-∞) b'3.9 darbiet.
English: Clinical data in healthy volunteers support CYP2C8 as being the most important enzyme involved in repaglinide metabolism with CYP3A4 playing a minor role, but the relative contribution of CYP3A4 can be increased if CYP2C8 is inhibited.
Maltese: Informazzjoni klinika f'voluntiera b'saħħithom tappoġġja l-fatt li CYP2C8 hi l-iktar enzima importanti involuta fil-metaboliżmu ta' repaglinide, b'CYP3A4 tilgħab rwol iżgħar, iżda lkontribuzzjoni relattiva ta' CYP3A4 tista' tiżdied jekk CYP2C8 tkun inibita.
English: Each tablet contains 0.5 mg repaglinide.
Maltese: Kull pillola fiha 0,5 mg repaglinide.
English: Repaglinide is eliminated rapidly within 4 - 6 hours from the blood.
Maltese: Repaglinide jiġi eliminat malajr mid-demm fi żmien 4-6 sigħat.
English: Rare (may affect up to 1 in 1,000 people): • Acute coronary syndrome (but it may not be due to the medicine).
Maltese: Rari (jistgħu jaffettwaw sa 1 minn kull 1000 persuna) - Sindromu koronarju akut (iżda jista' ma jkunux minħabba l-mediċina).
English: Detailed information on this medicine is available on the European Medicines Agency (EMA) web site: http://www.ema.europa.eu/.
Maltese: Informazzjoni dettaljata dwar dan il-prodott mediċinali tinsab fuq is-sit elettroniku tal-Aġenzija Ewropea għall-Mediċini http://www.ema.europa.eu/.
English: After a 5 day treatment of repaglinide (2 mg x 3/day) in patients with a severe impaired renal function (creatinine clearance: 20-39 ml/min.
Maltese: Wara kura ta' 5 tijiem b'repaglinide(2 mg x 3/ġurnata) f'pazjenti b'indeboliment renali gravi (tneħħija tal-krejatinina: 20-39 ml/min) ir-riżultati wrew żieda sinifikanti li kienu ta' darbtejn iżjed flespożizzjoni (AUC) u fil-half-life (t½), meta mqabbla ma' pazjenti b'funzjoni tal-kliewi normali.
English: In an interaction study in healthy volunteers, co-administration of 250 mg clarithromycin, a potent mechanism-based inhibitor of CYP3A4, slightly increased the repaglinide (AUC) by 1.4-fold and Cmax by 1.7-fold and increased the mean incremental AUC of serum insulin by 1.5-fold and the maximum concentration by 1.6-fold.
Maltese: Fi studju dwar l-interazzjoni bejn il-mediċini, li sar f'voluntiera b'saħħithom, it-teħid flimkien ma' 250 mg ta' clarithromycin, inibitur qawwi ta' CYP3A4 fuq livell ta' mekkaniżmu ta' azzjoni, żied bi ftit l-AUC ta' repaglinide b'1.4 darbiet u s-Cmax b'1.7 darbiet, u żied il-medja inkrementali ta' l-AUC ta' l-insulina tas-serum b'1.5 darbiet u lkonċentrazzjoni massima b'1.6 darbiet.
English: Co-administration of trimethoprim (160 mg twice daily), a moderate CYP2C8 inhibitor, and repaglinide (a single dose of 0.25 mg) increased the repaglinide AUC, Cmax and t½ (1.6-fold, 1.4-fold and 1.2-fold respectively) with no statistically significant effects on the blood glucose levels.
Maltese: Meta repaglinide (doża waħda ta' 0.25 mg) ingħata flimkien ma' trimethoprim(160 mg darbtejn kuljum), inibitur moderat ta' CYP2C8, kien hemm żieda fl-AUC, fis-Cmax u fit-t½ (1.6 darbiet, 1.4 darbiet u 1.2 darbiet rispettivament) ta' repaglinide, mingħajr ebda effett statistikament sinifikanti fuq il-livelli tal-glucose fid-demm.
English: Co-administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and repaglinide (a single dose of 0.25 mg) increased the repaglinide AUC 8.1-fold and Cmax 2.4-fold in healthy volunteers.
Maltese: Meta repaglinide (doża waħda ta' 0.25 mg) ingħata flimkien ma' gemfibrozil (600 mg darbtejn kuljum), inibitur ta' CYP2C8, kien hemm żieda fl-AUC ta' repaglinide ta' 8.1 darbiet u fis-Cmax ta' 2.4 darbiet f'voluntiera b'saħħithom.
English: • if you take gemfibrozil (a medicine used to lower increased fat levels in the blood).
Maltese: - Jekk tieħu gemfibrozil (mediċina biex tnaqqas il-livelli għoljin ta' xaħam fid-demm).
English: Swallow the tablets with a glass of water immediately before or up to 30 minutes before each main meal.
Maltese: Ibla' l-pillola ma' tazza ilma immedjatament qabel jew sa 30 minuta qabel kull ikla prinċipali.
English: Allergy
Maltese: Allerġija
English: Enyglid 0.5 mg tablets Each tablet contains 0.5 mg repaglinide.
Maltese: Enyglid 0,5 mg pilloli Kull pillola fiha 0,5 mg repaglinide.
English: Trials of combination therapy with NPH insulin or thiazolidinediones have been performed.
Maltese: Ġew magħmula studji ta' terapija kombinata ma' insulina Neutral Protamine Hagedorn (NPH) jew ma' thiazolidinediones.
English: Pharmaco-therapeutic group: Drugs used in diabetes, other blood glucose lowering drugs, excl. insulins, ATC code: A10BX02
Maltese: Mediċini użati fid-dijabete, mediċini oħra li jnaqqsu l-livell taz-zokkor fid-demm, li mhumiex insulini, Kodiċi ATC:
English: - Severe hepatic function disorder.
Maltese: - Disturbi severi fil-funzjoni tal-fwied.
English: The recommended maximum single dose is 4 mg taken with main meals.
Maltese: Id-doża singolari massima rakkomandata hi ta' 4 mg li tingħata mal-ikliet prinċipali.
English: In the case of concomitant use with other active substances refer to sections 4.4 and 4.5 to assess the dosage.
Maltese: F'każ ta' użu fl-istess ħin ta' sustanzi attivi oħra irreferi għal sezzjonijiet 4.4 u 4.5 biex tiċċekkja ddożaġġ.
English: There is no reason to suspect cross-allergenicity with sulphonylurea due to the difference in chemical structure.
Maltese: Ma hemm l-ebda raġuni għalxiex għandu jkun hemm xi suspett ta' allerġija trasversali mal-mediċini tat-tip sulphonylurea peress li għandhom struttura kimika differenti.
English: Breast-feeding
Maltese: Il-Manufattur
English: The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines webportal.
Maltese: Ir-rekwiżiti biex jiġu ppreżentati rapporti perjodiċi aġġornati dwar is-sigurtà għal dan il-prodott mediċinali huma mniżżla fil-lista tad-dati ta' referenza tal-Unjoni (lista EURD) prevista skont lArtikolu 107c(7) tad-Direttiva 2001/83/KE u kwalunkwe aġġornament sussegwenti ppubblikat fuq ilportal elettroniku Ewropew tal-mediċini.
English: Each tablet contains 2 mg repaglinide.
Maltese: Kull pillola fiha 2 mg repaglinide.
English: In a study conducted in healthy volunteers, the concomitant administration of repaglinide (a single dose of 0.25 mg) and ciclosporin (repeated dose at 100 mg) increased repaglinide AUC and Cmax about 2.5-fold and 1.8-fold respectively.
Maltese: F'studju magħmul f'volontiera b'saħħithom, l-għoti fl-istess ħin ta' repaglinide (doża waħda ta' 0.25 mg) u ciclosporin (doża ripetuta ta' 100 mg) żied l-AUC u s-Cmax ta' repaglinide b'madwar 2.5 u 1.8 darbiet rispettivament.
English: Enyglid 1 mg tablets Each tablet contains 1 mg repaglinide.
Maltese: Enyglid 1 mg pilloli Kull pillola fiha 1 mg repaglinide.
English: Enyglid 2 mg tablets Each tablet contains 2 mg repaglinide.
Maltese: Enyglid 2 mg pilloli Kull pillola fiha 2 mg repaglinide.
English: Each tablet contains 1 mg repaglinide.
Maltese: Kull pillola fiha 1 mg repaglinide.
English: Seven days pre-treatment with rifampicin (600 mg), followed by coadministration of repaglinide (a single dose of 4 mg) at day seven resulted in a 50% lower AUC (effect of a combined induction and inhibition).
Maltese: Kura minn qabel għal sebat ijiem b'rifampicin (600 mg), segwit b'teħid konkomitanti ta' repaglinide (doża waħda ta' 4 mg), fisseba' jum irriżulta f'tnaqqis ta' 50% fl'AUC (effett kemm ta' induzzjoni kif ukoll ta' inibizzjoni).
English: Repaglinide should be used with caution or be avoided in patients receiving medicinal products which influence repaglinide metabolism (see section 4.5).
Maltese: Repaglinide għandu jintuża b'kawtela jew jiġi evitat f'pazjenti li jirċievu prodotti mediċinali li jinfluwenza l-metaboliżmu ta' repaglinide (ara sezzjoni 4.5).
English: E.J.
Maltese: C.
English: Generalised hypersensitivity reactions (e.g. anaphylactic reaction), or immunological reactions such as vasculitis.
Maltese: Reazzjonijiet ta' sensittività eċċessiva ġeneralizzati (eż.reazzjoni anafilattika) jew reazzjonijiet immunoloġiċi bħal vaskulite
English: Povidone K25
Maltese: Informazzjoni għall-pazjent
English: KRKA Sverige AB Sími: + 46 (0)8 643 67 66 (SE)
Maltese: Sími: + 46 (0)8 643 67 66 (SE)
English: Periodic monitoring is necessary to detect inadequate lowering of blood glucose at the recommended maximum dose level (i.e. primary failure) and to detect loss of adequate blood-glucose lowering response after an initial period of effectiveness (i.e. secondary failure).
Maltese: Monitoraġġ perijodiku huwa meħtieġ sabiex jiġi magħruf l-ammont inadegwat imnaqqas ta' zokkor fil-livell massimu ta' doża rakkomandata (i.e. insuffiċjenza primarja) u sabiex jiġi mnaqqas ir-rispons għal tnaqqis adegwat ta' zokkor wara perijodu inizjali ta' effettività (i.e. insuffiċjenza sekondarja).
English: Patients receiving other oral hypoglycaemic medicinal products Patients can be transferred directly from other oral hypoglycaemic medicinal products to repaglinide.
Maltese: Pazjenti li qed jirċievu prodotti mediċinali ipogliċemiċi orali oħra Pazjenti jistgħu jiġu trasferiti direttament minn prodotti mediċinali ipogliċemiċi orali oħra għal repaglinide.
English: Repaglinide had no clinically relevant effect on the pharmacokinetic properties of digoxin, theophylline or warfarin at steady state, when administered to healthy volunteers.
Maltese: Repaglinide ma kellu l-ebda effett kliniku rilevanti fuq il-karatteristiċi farmakokinetiċi ta' digoxin,theophylline jew warfarin fi stat fiss, meta ngħata lill-voluntiera b'saħħithom.
English: Repaglinide is rapidly absorbed from the gastrointestinal tract, which leads to a rapid increase in the plasma concentration of the active substance.
Maltese: Repaglinide jiġi assorbit malajr mill-passaġġ gastrointestinali, li jwassal għal żieda b'mod mgħaġġel fil-konċentrazzjoni tas-sustanza attiva fil-plażma.
English: Since the safety profile of this combination has not been established with dosages higher than 0.25 mg for repaglinide and 320 mg for trimethoprim, the concomitant use of trimethoprim with repaglinide should be avoided.
Maltese: Minħabba li l-profil tas-sigurtà ta' din ilkombinazzjoni ma ġiex stabbilit b'doża ogħla minn 0.25 mg għal repaglinide u b'doża ogħla minn 320 mg għal trimethoprim, l-użu fl-istess ħin ta' trimethoprim ma' repaglinide għandu jiġi evitat.
English: As insulin sensitivity is increased in diabetic patients with renal impairment, caution is advised when titrating these patients.
Maltese: Indeboliment epatiku Ma sarux studji kliniċi f'pazjenti b'insuffiċjenza epatika.
English: When a patient stabilised on any oral hypoglycaemic medicinal product is exposed to stress such as fever, trauma, infection or surgery, a loss of glycaemic control may occur.
Maltese: Meta pazjent stabbilizzat fuq xi prodott mediċinali ipogliċemiku orali jiġi espost għal xi tip ta' stress bħal deni, trawma, infezzjoni jew kirurġija, jista' jintilef il-kontroll gliċemiku.
English: Abnormal hepatic function, increased liver enzymes Isolated cases of increased liver enzymes have been reported during treatment with repaglinide.
Maltese: Funzjoni epatika mhux normali, żieda fil-livelli tal-enzimi tal-fwied Każijiet iżolati ta' żieda fl-enzimi tal-fwied ġew irrappurtati waqt kura b'repaglinide.
English: Repaglinide closes ATP-dependent potassium channels in the β-cell membrane via a target protein different from other secretagogues.
Maltese: Repaglinide jagħlaq il-kanali tal-potassju dipendenti fuq l-ATP fil-membrana taċ-ċelloli  permezz ta' proteina partikolari li hija differenti minn prodotti oħra li jikkawżaw is-sekrezzjoni ta' l-insulina.
English: The concomitant use of gemfibrozil and repaglinide is contraindicated (see section 4.3).
Maltese: L-użu ta' gemfibrozil flimkien ma' repaglinide huwa kontraindikat (ara sezzjoni 4.3).
English: Concomitant use of rifampicin and repaglinide might therefore induce a need for repaglinide dose adjustment which should be based on carefully monitored blood glucose concentrations at both initiation of rifampicin treatment (acute inhibition), following dosing (mixed inhibition and induction), withdrawal (induction alone) and up to approximately two weeks after withdrawal of rifampicin where the inductive effect of rifampicin is no longer present.
Maltese: Dan għandu jkun ibbażat fuq il-konċentrazzjonijiet tal-glucose fid-demm li jkunu mmonitorjati bir-reqqa, kemm fil-bidu talkura b'rifampicin (inibizzjoni akuta), kemm fid-dożi suċċessivi (taħlita ta' inibizzjoni u induzzjoni), kemm meta titwaqqaf il-kura (induzzjoni waħidha) u kif ukoll sa madwar ġimagħtejn wara li titwaqqaf il-kura b'rifampicin, meta l-effett induttiv ta' rifampicin ma jkunx għadu hemm.
English: • if you have kidney problems.
Maltese: Enyglid). - jekk għandek problemi tal-kliewi.
English: 30 tablets: EU/1/09/580/007
Maltese: EU/1/09/580/007
English: - Diabetic ketoacidosis, with or without coma.
Maltese: terapiji kombinati oħra.
English: 30 tablets: EU/1/09/580/013
Maltese: EU/1/09/580/013
English: A small fraction (less than 8%) of the administered dose appears in the urine, primarily as metabolites.
Maltese: Frazzjoni żgħira (anqas minn 8%) tad-doża mogħtija tidher fl-awrina, primarjament bħala metaboli.
English: - Diabetes mellitus type 1, C-peptide negative.
Maltese: - Sensittività eċċessiva għal repaglinide jew għal kwalunkwe wieћed mill-eċċipjenti elenkati fis sezzjoni 6.1. - Dijabete mellitus tat-tip 1, C-peptide negattiv.
English: OUTER CARTON
Maltese: KARTUNA
English: • St.John's wort (herbal medicine).
Maltese: John's wort, jista' jkollhom effett simili.
English: • Clarithromycin, trimethoprim, rifampicin (antibiotic medicines).
Maltese: Numru ta' prodotti mediċinali huma magħrufa li jinfluwenzaw il-metaboliżmu ta' repaglinide.
English: • The dose may be adjusted by your doctor by up to 4 mg to be taken immediately before or up to 30 minutes before each main meal.
Maltese: - It-tabib tiegħek jista' jżid din sa 4 mg li jistgħu jittieħdu eżatt qabel jew sa 30 minuta wara kull ikla prinċipali.
English: 60 tablets: EU/1/09/580/014
Maltese: EU/1/09/580/014